Back

Venous thromboembolism in five-year cancer survivors: a nationwide cohort study

29 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Evolving cardiovascular complications in cancer survivors: vascular and cardiometabolic risks Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Adelina Yafasova

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Cardiopulmonary health risks among survivors of hematopoietic stem cell transplantation: a population-based cohort study
Doctor D. Condurache (London, GB)
Abstract Slides Video
Presentation thumbnail
Phenotypic clustering of allogeneic hematopoietic stem cell transplant recipients associated with cardiovascular events
Doctor T. Goncalves (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Cardiovascular Risk of Adjuvant Endocrine Therapy Plus Ovarian Suppression in Premenopausal Women with Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Doctor C. Fischer Bacca (Rio do Sul, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Evolving cardiovascular complications in cancer survivors: vascular and cardiometabolic risks
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Age- and sex- specific rate of venous thromboembolism in cancer survivors: a nationwide cohort study
25 August 2023
thumbnail
Congress Presentation
Ischemic stroke in patients with cancer: impact of atrial fibrillation in a nationwide register-based study
29 August 2026
thumbnail
Congress Presentation
Increased risk of long-term mortality following pulmonary embolism in Denmark, 2000-2020: A nationwide trend study.
26 August 2022
thumbnail
Congress Presentation
Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources